- Zacks via Yahoo FinanceApr 11 13:27 PM
Biotech bigwig Regeneron Pharmaceuticals, Inc. s REGN recently extended collaboration agreement with Alnylam Pharmaceuticals, Inc. ALNY brought ribonucleic acid interference (RNAi) therapeutics in focus.
Arrowhead Begins Triple Combination Cohort in Chronic HBV Patients and Earns $25 Million Milestone Payment from JanssenMarket Watch2 days ago
- Market Watch4 hours ago
Know the Growth Factor of Constipation Treatment Drug Market Size 2025: AstraZeneca, Bayer AG, Sanofi, Sucampo Pharmaceuticals, Inc., TakedaMarket Watch1 day ago
The Daily Biotech Pulse: J&J Earnings, FDA Nod For Medicinova, Proteon To Explore Strategic AlternativesBenzinga via Yahoo FinanceApr 16 12:10 PM
...: ASMB)(presented interim mid-stage results of its hepatitis B virus treatment candidate ABI-H0731) CELLECT BIOTECH/S ADR (NASDAQ: APOP) Conatus Pharmaceuticals Inc (NASDAQ: CNAT)(announced Phase 2 clinical trial evaluating emricasan in NASH patients with cirrhosis and severe portal hypertension) Fennec Pharmaceuticals Inc (NASDAQ: FENC...
- Zacks via Yahoo FinanceApr 16 14:54 PM
This kit will be used as a companion diagnostic to identify patients eligible for the treatment with Janssen Biotech’s fibroblast growth factor receptor (FGFR) kinase inhibitor drug, ...
- Thomson Reuters StreetEvents via Yahoo FinanceApr 17 16:11 PM
We recently issued our 2018 Janssen U.S. Transparency Report which is now available on our website. We led the industry by publishing this annual report 3 years ago, and we're proud to ...